Clarivate deals report highlights emerging trends in biopharma deal-making

Rna, cell & gene therapies, artificial intelligence, crispr and oncology related deals dominate the landscape biotech companies in u.s. awarded largest sums of capital, followed by mainland china and uk london , march 14, 2022 /prnewswire/ -- clarivate plc (nyse: clvt), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, biopharma deals in review: review of an extraordinary 2021 and expectations for the future biopharma deals , which highlights emerging market trends and features detailed analysis of the key deals of 2021 and potential implications for 2022. this year's report finds rna, cell & gene therapies, ai, crispr and oncology related deals dominated the landscape in 2021.
CLVT Ratings Summary
CLVT Quant Ranking